PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 8096664

[Salazopyrine desensitization].

P Schydlowsky
View original source ↗Export metadata ↓

Abstract

Salazopyrin is effective in the management of connective tissue diseases, it is safe and useful for long-term management. However, it's use may be complicated by a skin rash which may necessitate withdrawal of therapy. Four patients with connective tissue diseases were treated with salazopyrin in desensitisation doses, as management with full dosage had previously been followed by a skin rash. In two patients, we were able to achieve a daily dosage of 2 g salazopyrin, in one case therapy was continued with a lower dosage, and withdrawal of the drug proved necessary in one patient. Desensitisation of salazopyrin induced rash is an easy procedure and is, possible in most cases. It may be worthwhile for many patients.

Explore related subjects

Connective Tissue DiseasesDesensitization, ImmunologicExanthemaFemaleHumansMaleSulfasalazineEnglish AbstractJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

P Schydlowsky. 1993-02-15. [Salazopyrine desensitization].. https://pubmed.ncbi.nlm.nih.gov/8096664/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Joint hypermobility.

Patients with joint hypermobility, perhaps the mildest of the various inherited abnormalities of connective tissue, may present to a rheumatologist or general practitioner although a large proportion are recognized by health professionals, particularly physiotherapists. Hypermobility may be generalized or extreme at a small number of joints. Sometimes it is associated with involvement of other organs because of abnormal inherited collagen structure elsewhere. A small proportion of patients will have one of the more serious conditions such as Ehlers-Danlos syndrome, Marfan's syndrome or osteogenesis imperfecta. Management is multidisciplinary requiring a team including physicians, physiotherapists, occupational therapists and podiatrists, among others. Patients often wait a long time before receiving their definitive diagnosis and are sometimes dismissed as malingerers. Patients often have a lot of queries about their condition unrelated to their joints. Among these are whether there will be problems in pregnancy, whether the condition will be passed on to their children, whether symptoms arising from organs other than the joints are related and whether they might have been incorrectly accused of battering their children.

Connective Tissue Diseases↗
PubMed2007

Peripheral nervous system lesion syndromes and the mechanisms of their formation in connective tissue diseases.

Systemic rheumatological diseases are often accompanied by the development of central and peripheral nervous system pathology. Data providing evidence of the high incidence of peripheral nervous system lesions in systemic lupus erythematosus and systemic scleroderma are presented. These diseases in particular are characterized by polyneuropathies and tunnel syndromes. Our own observations, along with published data, revealed the following major pathogenetic mechanisms of peripheral nervous system lesions in diffuse connective tissue diseases - ischemic, immunological, and metabolic. Consideration of these mechanisms will lead to pathogenetically based treatment and improved therapeutic outcomes.

Connective Tissue Diseases↗
PubMed2006

Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review.

Patients suffering from connective tissue diseases (CTDs) constitute an important subgroup of immunosuppressed patients at risk for developing serious infections. Prophylactic antibiotic administration may decrease infection-related morbidity and mortality burden in patients with CTD, though one needs first to evaluate the overall effect of infection on morbidity and mortality in such patients and the presence of adequate prognostic/risk factors for infection development. Studies focusing on infection-related morbidity and mortality in patients with CTD were reviewed. Data on disease type, therapeutic regimens used, including corticosteroid dose and method of administration as well as other immunosuppressive agents, and outcome were extracted to evaluate the existence of specific treatment patterns predisposing to infection as well as infectious disease-related morbidity and mortality in patients with CTD. Thirty-nine studies focusing on infection incidence and/or outcome in patients with CTD were identified and analyzed; the majority of the reviewed studies (20) included patients with systemic lupus erythematosus (SLE). The mortality attributed to infection was 5.2%, while the overall mortality was 20%. There were no adequate data on the specific effect patterns of corticosteroid and immunosuppressant treatment on infection risk. Pneumocystis jiroveci (carinii) pneumonia, evaluated independently, exhibited significant mortality in patients with Wegener's granulomatosis, polymyositis/dermatomyositis, and SLE. In conclusion, infectious diseases are a major cause of mortality in patients with CTD. However, treatment-related factors predisposing to serious infections have not been adequately outlined. In addition, there are no data regarding the effect of prophylactic practices involving antibiotic administration in morbidity and mortality.

Connective Tissue Diseases↗